SEC Filings | Nurix Therapeutics, Inc.

Corporate Profile

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of innovative small molecules and antibody therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer, inflammatory conditions, and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date	Description	Form	View
March 05, 2021	POS EX	POS EX	0001193125-21-071442.pdf 0001193125-21-071442.rtf 0001193125-21-071442.xls View HTML
February 09, 2023	Post-effective amendment to an S-Type filing	POS AM	0001193125-23-030326.pdf 0001193125-23-030326.rtf 0001193125-23-030326.xls View HTML
July 23, 2020	EFFECT	EFFECT	9999999995-20-001903.xls View HTML
March 04, 2021	EFFECT	EFFECT	9999999995-21-000848.pdf 9999999995-21-000848.rtf 9999999995-21-000848.xls View HTML
April 06, 2023	EFFECT	EFFECT	9999999995-23-000840.pdf 9999999995-23-000840.rtf 9999999995-23-000840.xls View HTML
June 10, 2020	Amendment to a previously filed DRS	DRS/A	0000950123-20-006168.pdf 0000950123-20-006168.rtf 0000950123-20-006168.xls View HTML
May 05, 2020	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	DRS	0000950123-20-003951.pdf 0000950123-20-003951.rtf 0000950123-20-003951.xls View HTML
February 22, 2021	Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy	DRS	0000950123-21-003063.pdf 0000950123-21-003063.rtf 0000950123-21-003063.xls View HTML
March 25, 2021	Additional proxy soliciting materials - definitive	DEFA14A	0001193125-21-093271.pdf 0001193125-21-093271.rtf 0001193125-21-093271.xls View HTML
March 25, 2022	Additional proxy soliciting materials - definitive	DEFA14A	0001193125-22-084525.pdf 0001193125-22-084525.rtf View HTML

Monday, May 20, 2024, at 9:30 AM Pacific Time

Nurix’s 2024 Annual Meeting of Stockholders will be held on Monday, May 20, 2024.

Stockholders of record of Nurix common stock as of the close of business on March 21, 2024, are entitled to vote at the meeting. The live webcast of the meeting will be accessible by visiting www.virtualshareholdermeeting.com/NRIX2024.

Copies of the CEO Letter, Proxy Statement and Annual Report to Shareholders for the 2024 Annual Meeting of Stockholders are available on the “Events and Presentations” page within the “Investors” section of our website.

Investors

Corporate Profile

2024

2023

2022

2021

2020

Monday, May 20, 2024, at 9:30 AM Pacific Time